X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA BIOCON LTD ALEMBIC PHARMA/
BIOCON LTD
 
P/E (TTM) x 26.8 36.5 73.4% View Chart
P/BV x 6.1 4.8 126.0% View Chart
Dividend Yield % 0.8 1.5 50.5%  

Financials

 ALEMBIC PHARMA   BIOCON LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
BIOCON LTD
Mar-16
ALEMBIC PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs792496 159.7%   
Low Rs443397 111.7%   
Sales per share (Unadj.) Rs167.0174.3 95.8%  
Earnings per share (Unadj.) Rs38.244.8 85.2%  
Cash flow per share (Unadj.) Rs42.056.9 73.8%  
Dividends per share (Unadj.) Rs4.005.00 80.0%  
Dividend yield (eoy) %0.61.1 57.8%  
Book value per share (Unadj.) Rs84.9202.8 41.9%  
Shares outstanding (eoy) m188.52200.00 94.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.72.6 144.4%   
Avg P/E ratio x16.210.0 162.5%  
P/CF ratio (eoy) x14.77.8 187.6%  
Price / Book Value ratio x7.32.2 330.5%  
Dividend payout %10.511.2 93.9%   
Avg Mkt Cap Rs m116,38389,220 130.4%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m4,2146,363 66.2%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m31,48734,854 90.3%  
Other income Rs m55845 6.5%   
Total revenues Rs m31,54235,699 88.4%   
Gross profit Rs m10,0608,200 122.7%  
Depreciation Rs m7222,423 29.8%   
Interest Rs m37102 36.1%   
Profit before tax Rs m9,3566,520 143.5%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m2,1602,569 84.1%   
Profit after tax Rs m7,1948,961 80.3%  
Gross profit margin %31.923.5 135.8%  
Effective tax rate %23.139.4 58.6%   
Net profit margin %22.825.7 88.9%  
BALANCE SHEET DATA
Current assets Rs m15,06639,932 37.7%   
Current liabilities Rs m7,67416,276 47.2%   
Net working cap to sales %23.567.9 34.6%  
Current ratio x2.02.5 80.0%  
Inventory Days Days6754 125.0%  
Debtors Days Days4186 47.1%  
Net fixed assets Rs m8,23739,101 21.1%   
Share capital Rs m3771,000 37.7%   
"Free" reserves Rs m15,41638,591 39.9%   
Net worth Rs m16,00540,556 39.5%   
Long term debt Rs m020,724 0.0%   
Total assets Rs m24,59484,816 29.0%  
Interest coverage x255.264.9 393.1%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.30.4 311.6%   
Return on assets %29.410.7 275.2%  
Return on equity %44.922.1 203.4%  
Return on capital %58.719.0 309.1%  
Exports to sales %55.730.7 181.3%   
Imports to sales %10.420.4 51.1%   
Exports (fob) Rs m17,55110,717 163.8%   
Imports (cif) Rs m3,2837,105 46.2%   
Fx inflow Rs m17,81111,789 151.1%   
Fx outflow Rs m5,3188,393 63.4%   
Net fx Rs m12,4933,396 367.9%   
CASH FLOW
From Operations Rs m9,3045,264 176.7%  
From Investments Rs m-3,105-9,540 32.5%  
From Financial Activity Rs m-1,95910,867 -18.0%  
Net Cashflow Rs m4,2406,591 64.3%  

Share Holding

Indian Promoters % 74.1 40.4 183.4%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 2.9 8.4 34.5%  
FIIs % 9.1 10.7 85.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 19.9 69.8%  
Shareholders   49,328 109,995 44.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 21, 2017 11:56 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS